SEARCH

SEARCH BY CITATION

References

  • 1
    Klues HG, Schiffers A, Maron BJ. Phenotypic spectrum and patterns of left ventricular hypertrophy in hypertrophic cardiomyopathy: morphologic observations and significance as assessed by two-dimensional echocardiography in 600 patients. J Am Coll Cardiol 1995;26:1699708.
  • 2
    Wang L, Seidman JG, Seidman CE. Narrative review: harnessing molecular genetics for the diagnosis and management of hypertrophic cardiomyopathy. Ann Intern Med 2010;152:51320.
  • 3
    Sachdev B, Takenaka T, Teraguchi H, Tei C, Lee P, McKenna WJ et al. Prevalence of Anderson-Fabry disease in male patients with late onset hypertrophic cardiomyopathy. Circulation 2002;105:140711.
  • 4
    Maron BJ, Roberts WC, Arad M, Haas TS, Spirito P, Wright GB et al. Clinical outcome and phenotypic expression in LAMP2 cardiomyopathy. JAMA 2009;301:12539.
  • 5
    Van den Hout H, Reuser AJ, Vulto AG, Christa BL, Cromme-Dijkhuis A, Van der Ploeg AT. Recombinant human [alpha]-glucosidase from rabbit milk in Pompe patients. Lancet 2000;356:3978.
  • 6
    Arad M, Maron BJ, Gorham JM, Johnson WH, Saul JP, Perez-Atayde AR et al. Glycogen storage diseases presenting as hypertrophic cardiomyopathy. N Engl J Med 2005;352:36272.
  • 7
    Seward JB, Casaclang-Verzosa G. Infiltrative cardiovascular diseases: cardiomyopathies that look alike. J Am Coll Cardiol 2010;55:176979.
  • 8
    Odawara M, Yamashita K. Mitochondrial DNA abnormalities in hypertrophic cardiomyopathy. Lancet 1999;353:150.
  • 9
    Marian AJ, Roberts R. To screen or not is not the question – it is when and how to screen. Circulation 2003;107:21714.
  • 10
    Germans T, Wilde AAM, Dijkmans PA, Chai W, Kamp O, Pinto YM et al. Structural abnormalities of the inferoseptal left ventricular wall detected by cardiac magnetic resonance imaging in carriers of hypertrophic cardiomyopathy mutations. J Am Coll Cardiol 2006;48:251823.
  • 11
    Nagueh SF, Bachinski LL, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue doppler imaging consistently detects myocardial abnormalities in patients with hypertrophic cardiomyopathy and provides a novel means for an early diagnosis before and independently of hypertrophy. Circulation 2001;104:12830.
  • 12
    Nagueh SF, McFalls J, Meyer D, Hill R, Zoghbi WA, Tam JW et al. Tissue doppler imaging predicts the development of hypertrophic cardiomyopathy in subjects with subclinical disease. Circulation 2003;108:3958.
  • 13
    Ho CY, Sweitzer NK, McDonough B, Maron BJ, Casey SA, Seidman JG et al. Assessment of diastolic function with doppler tissue imaging to predict genotype in preclinical hypertrophic cardiomyopathy. Circulation 2002;105:29927.
  • 14
    Michels M, Soliman OII, Kofflard MJ, Hoedemaekers YM, Dooijes D, Majoor-Krakauer D et al. Diastolic abnormalities as the first feature of hypertrophic cardiomyopathy in Dutch myosin-binding protein C founder mutations. JACC Cardiovasc Imaging 2009;2:5864.
  • 15
    Gandjbakhch E, Gackowski A, Tezenas du Montcel S, Isnard R, Hamroun A, Richard P et al. Early identification of mutation carriers in familial hypertrophic cardiomyopathy by combined echocardiography and tissue Doppler imaging. Eur Heart J 2010;13:1599607.
  • 16
    Germans T, Russel IK, Gotte MJ, Spreeuwenberg MD, Doevendans PA, Pinto YM et al. How do hypertrophic cardiomyopathy mutations affect myocardial function in carriers with normal wall thickness? Assessment with cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2010;12:13.
  • 17
    Kuribayashi T, Roberts WC. Myocardial disarray at junction of ventricular septum and left and right ventricular free walls in hypertrophic cardiomyopathy. Am J Cardiol 1992;70:133340.
  • 18
    Johansson B, Maceira AM, Babu-Narayan SV, Moon JC, Pennell DJ, Kilner PJ. Clefts can be seen in the basal inferior wall of the left ventricle and the interventricular septum in healthy volunteers as well as patients by cardiovascular magnetic resonance. J Am Coll Cardiol 2007;50:12945.
  • 19
    Maron BJ, Lindberg J, Lesser JR. Ventricular septal crypt in hypertrophic cardiomyopathy. Eur Heart J 2010;15:1923.
  • 20
    Varnava AM, Elliott PM, Baboonian C, Davison F, Davies MJ, McKenna WJ. Hypertrophic cardiomyopathy: histopathological features of sudden death in cardiac troponin T disease. Circulation 2001;104:13804.
  • 21
    Ho CY, Solomon SD. A clinician’s guide to tissue doppler imaging. Circulation 2006;113:e3968.
  • 22
    Ho CY, Lopez B, Coelho-Filho OR, Lakdawala NK, Cirino AL, Jarolim P et al. Myocardial fibrosis as an early manifestation of hypertrophic cardiomyopathy. N Engl J Med 2010;363:55263.
  • 23
    Kim JB, Porreca GJ, Song L, Greenway SC, Gorham JM, Church GM et al. Polony multiplex analysis of gene expression (PMAGE) in mouse hypertrophic cardiomyopathy. Science 2007;316:14814.
  • 24
    Niimura H, Bachinski LL, Sangwatanaroj S, Watkins H, Chudley AE, McKenna W et al. Mutations in the gene for cardiac myosin-binding protein C and late-onset familial hypertrophic cardiomyopathy. N Engl J Med 1998;338:124857.
  • 25
    Maron BJ, Niimura H, Casey SA, Soper MK, Wright GB, Seidman JG et al. Development of left ventricular hypertrophy in adults with hypertrophic cardiomyopathy caused by cardiac myosin-binding protein C gene mutations. J Am Coll Cardiol 2001;38:31521.
  • 26
    Morita H, Rehm HL, Menesses A, McDonough B, Roberts AE, Kucherlapati R et al. Shared genetic causes of cardiac hypertrophy in children and adults. N Engl J Med 2009;358:1899908.
  • 27
    Nugent AW, Daubeney PEF, Chondros P, Carlin JB, Colan SD, Cheung M et al. Clinical features and outcomes of childhood hypertrophic cardiomyopathy: results from a national population-based study. Circulation 2005;112:13328.
  • 28
    Rottbauer W, Gautel M, Zehelein J, Labeit S, Franz WM, Fischer C et al. Novel splice donor site mutation in the cardiac myosin-binding protein-C gene in familial hypertrophic cardiomyopathy. Characterization Of cardiac transcript and protein. J Clin Invest 1997;100:47582.
  • 29
    Moolman JA, Reith S, Uhl K, Bailey S, Gautel M, Jeschke B et al. A newly created splice donor site in exon 25 of the MyBP-C gene is responsible for inherited hypertrophic cardiomyopathy with incomplete disease penetrance. Circulation 2000;101:1396402.
  • 30
    van Dijk SJ, Dooijes D, dos Remedios C, Michels M, Lamers JMJ, Winegrad S et al. Cardiac myosin-binding protein C mutations and hypertrophic cardiomyopathy: haploinsufficiency, deranged phosphorylation, and cardiomyocyte dysfunction. Circulation 2009;119:147383.
  • 31
    Marston S, Copeland O’N, Jacques A, Livesey K, Tsang V, McKenna WJ et al. Evidence from human myectomy samples that MYBPC3 mutations cause hypertrophic cardiomyopathy through haploinsufficiency. Circ Res 2009;105:21922.
  • 32
    Tardiff J. Sarcomeric proteins and familial hypertrophic cardiomyopathy: linking mutations in structural proteins to complex cardiovascular phenotypes. Heart Fail Rev 2005;10:23748.
  • 33
    Robinson P, Griffiths PJ, Watkins H, Redwood CS. Dilated and hypertrophic cardiomyopathy mutations in Troponin and {alpha}-Tropomyosin have opposing effects on the calcium affinity of cardiac thin filaments. Circ Res 2007;101:126673.
  • 34
    Marian AJ, Roberts R. Molecular genetic basis of hypertrophic cardiomyopathy: genetic markers for sudden cardiac death. J Cardiovasc Electrophysiol 1998;9:8899.
  • 35
    Ashrafian H, Redwood C, Blair E, Watkins H. Hypertrophic cardiomyopathy:a paradigm for myocardial energy depletion. Trends Genet 2003;19:2638.
  • 36
    Crilley JG, Boehm EA, Blair E, Rajagopalan B, Blamire AM, Styles P et al. Hypertrophic cardiomyopathy due to sarcomeric gene mutations is characterized by impaired energy metabolism irrespective of the degree of hypertrophy. J Am Coll Cardiol 2003;41:177682.
  • 37
    Heineke J, Molkentin JD. Regulation of cardiac hypertrophy by intracellular signalling pathways. Nat Rev Mol Cell Biol 2006;7:589600.
  • 38
    Rohini A, Agrawal N, Koyani CN, Singh R. Molecular targets and regulators of cardiac hypertrophy. Pharmacol Res 2010;61:26980.
  • 39
    Sussman MA, Lim HW, Gude N, Taigen T, Olson EN, Robbins J et al. Prevention of cardiac hypertrophy in mice by calcineurin inhibition. Science 1998;281:16903.
  • 40
    Lim HW, De Windt LJ, Mante J, Kimball TR, Witt SA, Sussman MA et al. Reversal of cardiac hypertrophy in transgenic disease models by calcineurin inhibition. J Mol Cell Cardiol 2000;32:697709.
  • 41
    Schmitt JP, Semsarian C, Arad M, Gannon J, Ahmad F, Duffy C et al. Consequences of pressure overload on sarcomere protein mutation-induced hypertrophic cardiomyopathy. Circulation 2003;108:11338.
  • 42
    Ventura HO, Malik FS, Mehra MR, Stapleton DD, Smart FW. Mechanisms of hypertension in cardiac transplantation and the role of cyclosporine. Curr Opin Cardiol 1997;12:37581.
  • 43
    Marian AJ, Senthil V, Chen SN, Lombardi R. Antifibrotic effects of antioxidant N-Acetylcysteine in a mouse model of human hypertrophic cardiomyopathy mutation. J Am Coll Cardiol 2006;47:82734.
  • 44
    Dimitrow PP, Undas A, Wolkow P, Tracz W, Dubiel JS. Enhanced oxidative stress in hypertrophic cardiomyopathy. Pharmacol Rep 2009;61:4915.
  • 45
    Nakamura K, Kusano KF, Matsubara H, Nakamura Y, Miura A, Nishii N et al. Relationship between oxidative stress and systolic dysfunction in patients with hypertrophic cardiomyopathy. J Card Fail 2005;11:11723.
  • 46
    Lombardi R, Rodriguez G, Chen SN, Ripplinger CM, Li W, Chen J et al. Resolution of established cardiac hypertrophy and fibrosis and prevention of systolic dysfunction in a transgenic rabbit model of human cardiomyopathy through thiol-sensitive mechanisms. Circulation 2009;119:1398407.
  • 47
    Teare D. Asymmetrical hypertrophy of the heart in young adults. Br Heart J 1958;1:18.
  • 48
    Maron BJ, Gottdiener JS, Epstein SE. Patterns and significance of distribution of left ventricular hypertrophy in hypertrophic cardiomyopathy. A wide angle, two dimensional echocardiographic study of 125 patients. Am J Cardiol 1981;48:41828.
  • 49
    Kitaoka H, Doi Y, Casey SA, Hitomi N, Furuno T, Maron BJ. Comparison of prevalence of apical hypertrophic cardiomyopathy in Japan and the United States. Am J Cardiol 2003;92:11836.
  • 50
    Yang H, Carasso S, Woo A, Jamorski M, Nikonova A, Wigle ED et al. Hypertrophy pattern and regional myocardial mechanics are related in septal and apical hypertrophic cardiomyopathy. J Am Soc Echocardiogr 2010;10:10819.
  • 51
    Petersen SE, Selvanayagam JB, Francis JM, Myerson SG, Wiesmann F, Robson MD et al. Differentiation of athlete’s heart from pathological forms of cardiac hypertrophy by means of geometric indices derived from cardiovascular magnetic resonance. J Cardiovasc Magn Reson 2005;7:5518.
  • 52
    Pluim BM, Lamb HJ, Kayser HWM, Leujes F, Beyerbacht HP, Zwinderman AH et al. Functional and metabolic evaluation of the athlete’s heart by magnetic resonance imaging and dobutamine stress magnetic resonance spectroscopy. Circulation 1998;97:66672.
  • 53
    Rickers C, Wilke NM, Jerosch-Herold M, Casey SA, Panse P, Panse N et al. Utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation 2005;112:85561.
  • 54
    Marian AJ. Pathogenesis of diverse clinical and pathological phenotypes in hypertrophic cardiomyopathy. Lancet 2000;355:5860.
  • 55
    Tsybouleva N, Zhang L, Chen S, Patel R, Lutucuta S, Nemoto S et al. Aldosterone, through novel signaling proteins, is a fundamental molecular bridge between the genetic defect and the cardiac phenotype of hypertrophic cardiomyopathy. Circulation 2004;109:128491.
  • 56
    Basso C, Thiene G, Corrado D, Buja G, Melacini P, Nava A. Hypertrophic cardiomyopathy and sudden death in the young: pathologic evidence of myocardial ischemia. Hum Pathol 2000;31:98898.
  • 57
    Petersen SE, Jerosch-Herold M, Hudsmith LE, Robson MD, Francis JM, Doll HA et al. Evidence for microvascular dysfunction in hypertrophic cardiomyopathy: new insights from multiparametric magnetic resonance imaging. Circulation 2007;115:241825.
  • 58
    Kwon DH, Smedira NG, Rodriguez ER, Tan C, Setser R, Thamilarasan M et al. Cardiac magnetic resonance detection of myocardial scarring in hypertrophic cardiomyopathy: correlation with histopathology and prevalence of ventricular tachycardia. J Am Coll Cardiol 2009;54:2429.
  • 59
    Moon JCC, Reed E, Sheppard MN, Elkington AG, Ho S, Burke M et al. The histologic basis of late gadolinium enhancement cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;43:22604.
  • 60
    Knaapen P, van Dockum WG, Bondarenko O, Kok WEM, Gotte MJW, Boellaard R et al. Delayed contrast enhancement and perfusable tissue index in hypertrophic cardiomyopathy: comparison between cardiac MRI and PET. J Nucl Med 2005;46:9239.
  • 61
    Takagi E, Yamakado T, Nakano T. Prognosis of completely asymptomatic adult patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 1999;33:20611.
  • 62
    Wigle ED, Rakowski H, Kimball BP, Williams WG. Hypertrophic cardiomyopathy : clinical spectrum and treatment. Circulation 1995;92:168092.
  • 63
    Klues HG, Maron BJ, Dollar AL, Roberts WC. Diversity of structural mitral valve alterations in hypertrophic cardiomyopathy. Circulation 1992;85:165160.
  • 64
    He S, Hopmeyer J, Lefebvre XP, Schwammenthal E, Yoganathan AP, Levine RA. Importance of leaflet elongation in causing systolic anterior motion of the mitral valve. J Heart Valve Dis 1997;6:14959.
  • 65
    Maron MS, Olivotto I, Zenovich AG, Link MS, Pandian NG, Kuvin JT et al. Hypertrophic cardiomyopathy is predominantly a disease of left ventricular outflow tract obstruction. Circulation 2006;114:22329.
  • 66
    Harris KM, Spirito P, Maron MS, Zenovich AG, Formisano F, Lesser JR et al. Prevalence, clinical profile, and significance of left ventricular remodeling in the end-stage phase of hypertrophic cardiomyopathy. Circulation 2006;114:21625.
  • 67
    Maron MS, Finley JJ, Bos JM, Hauser TH, Manning WJ, Haas TS et al. Prevalence, clinical significance, and natural history of left ventricular apical aneurysms in hypertrophic cardiomyopathy. Circulation 2008;118:15419.
  • 68
    Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ. Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 2001;104:251724.
  • 69
    Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP et al. Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 2002;39:3017.
  • 70
    Melacini P, Basso C, Angelini A, Calore C, Bobbo F, Tokajuk B et al. Clinicopathological profiles of progressive heart failure in hypertrophic cardiomyopathy. Eur Heart J 2010;17:21113.
  • 71
    Losi MA, Betocchi S, Aversa M, Lombardi R, Miranda M, D’Alessandro G et al. Determinants of atrial fibrillation development in patients with hypertrophic cardiomyopathy. Am J Cardiol 2004;94:895900.
  • 72
    Papavassiliu T, Germans T, Fluchter S, Doesch C, Suriyakamar A, Haghi D et al. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson 2009;11:34.
  • 73
    Di Donna P, Olivotto I, Delcrè SDL, Caponi D, Scaglione M, Nault I et al. Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 2010;12:34755.
  • 74
    McKenna WJ, Camm AJ. Sudden death in hypertrophic cardiomyopathy. Assessment of patients at high risk. Circulation 1989;80:148992.
  • 75
    Spirito P, Maron BJ. Relation between extent of left ventricular hypertrophy and occurrence of sudden cardiac death in hypertrophic cardiomyopathy. J Am Coll Cardiol 1990;15:15216.
  • 76
    Spirito P, Bellone P, Harris KM, Bernabo P, Bruzzi P, Maron BJ. Magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med 2000;342:177885.
  • 77
    Christiaans I, Lekanne dit Deprez RH, van Langen IM, Wilde AAM. Ventricular fibrillation in MYH7-related hypertrophic cardiomyopathy before onset of ventricular hypertrophy. Heart Rhythm 2009;6:13669.
  • 78
    Watkins H, McKenna WJ, Thierfelder L, Suk HJ, Anan R, O’Donoghue A et al. Mutations in the genes for cardiac Troponin T and {alpha}-Tropomyosin in hypertrophic cardiomyopathy. N Engl J Med 1995;332:105865.
  • 79
    Adabag AS, Maron BJ, Appelbaum E, Harrigan CJ, Buros JL, Gibson CM et al. Occurrence and frequency of arrhythmias in hypertrophic cardiomyopathy in relation to delayed enhancement on cardiovascular magnetic resonance. J Am Coll Cardiol 2008;51:136974.
  • 80
    Rubinshtein R, Glockner JF, Ommen SR, Araoz PA, Ackerman MJ, Sorajja P et al. Characteristics and clinical significance of late gadolinium enhancement by contrast-enhanced magnetic resonance imaging in patients with hypertrophic cardiomyopathy. Circ Heart Fail 2010;3:518.
  • 81
    Maron BJ, Spirito P, Shen WK, Haas TS, Formisano F, Link MS et al. Implantable cardioverter-defibrillators and prevention of sudden cardiac death in hypertrophic cardiomyopathy. JAMA 2007;298:40512.
  • 82
    Maron BJ, McKenna WJ, Danielson GK, Kappenberger LJ, Kuhn HJ, Seidman CE et al. American College of Cardiology/European Society of Cardiology clinical expert consensus document on hypertrophic cardiomyopathy: a report of the American College of Cardiology foundation task force on clinical expert consensus documents and the European Society of Cardiology committee for practice guidelines. J Am Coll Cardiol 2003;42:1687713.
  • 83
    Ito T, Suwa M, Imai M, Hozumi T, Tonari S, Kitaura Y. Acute effects of diltiazem on regional left ventricular diastolic filling dynamics in patients with hypertrophic cardiomyopathy as assessed by color kinesis. Circ J 2004;68:103540.
  • 84
    Bonow RO, Rosing DR, Bacharach SL, Green MV, Kent KM, Lipson LC et al. Effects of verapamil on left ventricular systolic function and diastolic filling in patients with hypertrophic cardiomyopathy. Circulation 1981;64:78796.
  • 85
    Udelson JE, Bonow RO, O’Gara PT, Maron BJ, Van Lingen A, Bacharach SL et al. Verapamil prevents silent myocardial perfusion abnormalities during exercise in asymptomatic patients with hypertrophic cardiomyopathy. Circulation 1989;79:105260.
  • 86
    Epstein SE, Rosing DR. Verapamil: its potential for causing serious complications in patients with hypertrophic cardiomyopathy. Circulation 1981;64:43741.
  • 87
    Sherrid MV, Barac I, McKenna WJ, Elliott PM, Dickie S, Chojnowska L et al. Multicenter study of the efficacy and safety of disopyramide in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2005;45:12518.
  • 88
    Riccioni N, Castiglioni M, Bartolomei C. Disopyramide-induced QT prolongation and ventricular tachyarrhythmias. Am Heart J 1983;105:8701.
  • 89
    Maron BJ, Dearani JA, Ommen SR, Maron MS, Schaff HV, Gersh BJ et al. The case for surgery in obstructive hypertrophic cardiomyopathy. J Am Coll Cardiol 2004;44:204453.
  • 90
    Sigwart U. Non-surgical myocardial reduction for hypertrophic obstructive cardiomyopathy. Lancet 1995;346:2114.
  • 91
    ten Cate FJ, Soliman OI, Michels M, Theuns DA, de Jong PL, Geleijnse ML et al. Long-term outcome of alcohol septal ablation in patients with obstructive hypertrophic cardiomyopathy: a word of caution. Circ Heart Fail 2010;3:3629.
  • 92
    Yamazaki T, Komuro I, Yazaki Y. Role of the renin-angiotensin system in cardiac hypertrophy. Am J Cardiol 1999;83:53H7H.
  • 93
    Lim DS, Lutucuta S, Bachireddy P, Youker K, Evans A, Entman M et al. Angiotensin II blockade reverses myocardial fibrosis in a transgenic mouse model of human hypertrophic cardiomyopathy. Circulation 2001;103:78991.
  • 94
    Kawano H, Toda G, Nakamizo R, Koide Y, Seto S, Yano K. Valsartan decreases type I collagen synthesis in patients with hypertrophic cardiomyopathy. Circ J 2005;69:12448.
  • 95
    Yamazaki T, Suzuki J, Shimamoto R, Tsuji T, Ohmoto-Sekine Y, Ohtomo K et al. A new therapeutic strategy for hypertrophic nonobstructive cardiomyopathy in humans: a randomized and prospective study with an angiotensin II receptor blocker. Int Heart J 2007;48:71524.
  • 96
    Penicka M, Gregor P, Kerekes R, Marek D, Curila K, Krupicka J et al. The effects of candesartan on left ventricular hypertrophy and function in nonobstructive hypertrophic cardiomyopathy: a pilot, randomized study. J Mol Diagn 2009;11:3541.
  • 97
    Patel R, Nagueh SF, Tsybouleva N, Abdellatif M, Lutucuta S, Kopelen HA et al. Simvastatin induces regression of cardiac hypertrophy and fibrosis and improves cardiac function in a transgenic rabbit model of human hypertrophic cardiomyopathy. Circulation 2001;104:31724.
  • 98
    Semsarian C, Ahmad I, Giewat M, Georgakopoulos D, Schmitt JP, McConnell BK et al. The L-type calcium channel inhibitor diltiazem prevents cardiomyopathy in a mouse model. J Clin Invest 2002;109:101320.
  • 99
    Baudenbacher F, Schober T, Pinto JR, Sidorov VY, Hilliard F, Solaro RJ et al. Myofilament Ca2+ sensitization causes susceptibility to cardiac arrhythmia in mice. J Clin Invest 2008;118:3893903.
  • 100
    Kantor PF, Lucien A, Kozak R, Lopaschuk GD. The antianginal drug trimetazidine shifts cardiac energy metabolism from fatty acid oxidation to glucose oxidation by inhibiting mitochondrial long-chain 3-ketoacyl coenzyme A thiolase. Circ Res 2000;86:5808.
  • 101
    Timmer SA, Germans T, Gotte MJ, Russel IK, Dijkmans PA, Lubberink M et al. Determinants of myocardial energetics and efficiency in symptomatic hypertrophic cardiomyopathy. Eur J Nucl Med Mol Imaging 2010;37:77988.